AN OPEN-LABEL, PHASE 1/2 STUDY EVALUATING AVM0703 IN PATIENTS WITH LYMPHOID MALIGNANCIES (OPAL STUDY)

Registry ID

AVM0703-001

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

AVM BIOTECHNOLOGY, LLC

Last update

2023-02-22

Conditions

• LYMPHOID MALIGNANCIES

Related clinical trials

• A PHASE 1, DOSE-ESCALATION/DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF ORALLY ADMINISTERED CB-5083 IN SUBJECTS WITH LYMPHOID HEMATOLOGICAL MALIGNANCIES
• A PHASE I/II STUDY OF PEMBROLIZUMAB (MK-3475) IN CHILDREN WITH ADVANCED MELANOMA OR A PD-L1 POSITIVE ADVANCED, RELAPSED OR REFRACTORY SOLID TUMOR OR LYMPHOMA (KEYNOTE-051)

View on source registry